• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用感染诱导的细胞形态变化的动力学测量进行高通量传染性病毒滴度的测定。

High-Throughput Determination of Infectious Virus Titers by Kinetic Measurement of Infection-Induced Changes in Cell Morphology.

机构信息

Boehringer Ingelheim Pharma GmbH & Co. KG, Viral Therapeutics Center, 88397 Biberach an der Riss, Germany.

Boehringer Ingelheim Pharma GmbH & Co. KG, Development Biologicals, 88397 Biberach an der Riss, Germany.

出版信息

Int J Mol Sci. 2024 Jul 24;25(15):8076. doi: 10.3390/ijms25158076.

DOI:10.3390/ijms25158076
PMID:39125646
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11311753/
Abstract

Infectivity assays are the key analytical technology for the development and manufacturing of virus-based therapeutics. Here, we introduce a novel assay format that utilizes label-free bright-field images to determine the kinetics of infection-dependent changes in cell morphology. In particular, cell rounding is directly proportional to the amount of infectious virus applied, enabling rapid determination of viral titers in relation to a standard curve. Our kinetic infectious virus titer (KIT) assay is stability-indicating and, due to its sensitive readout method, provides results within 24 h post-infection. Compared to traditional infectivity assays, which depend on a single readout of an infection endpoint, cumulated analysis of kinetic data by a fit model results in precise results (CV < 20%) based on only three wells per sample. This approach allows for a high throughput with ~400 samples processed by a single operator per week. We demonstrate the applicability of the KIT assay for the genetically engineered oncolytic VSV-GP, Newcastle disease virus (NDV), and parapoxvirus ovis (ORFV), but it can potentially be extended to a wide range of viruses that induce morphological changes upon infection. The versatility of this assay, combined with its independence from specific instruments or software, makes it a promising solution to overcome the analytical bottleneck in infectivity assays within the pharmaceutical industry and as a routine method in academic research.

摘要

感染力分析是开发和制造基于病毒的治疗药物的关键分析技术。在这里,我们介绍了一种新颖的分析方法,利用无标记明场图像来确定感染依赖性细胞形态变化的动力学。特别是,细胞圆化与应用的传染性病毒量成正比,能够快速确定与标准曲线相关的病毒滴度。我们的动力学传染性病毒滴度 (KIT) 分析是稳定性指示的,并且由于其敏感的读数方法,在感染后 24 小时内提供结果。与传统的感染分析相比,该分析依赖于感染终点的单次读数,通过拟合模型对动力学数据进行累积分析,可以根据每个样本仅三个孔的结果得出精确的结果(CV<20%)。这种方法允许每个操作人员每周处理约 400 个样本,具有高通量的特点。我们证明了 KIT 分析在基因工程溶瘤性 VSV-GP、新城疫病毒 (NDV) 和绵羊痘病毒 (ORFV) 中的适用性,但它可以潜在地扩展到能够诱导感染后形态变化的广泛病毒。该分析方法的多功能性,结合其对特定仪器或软件的独立性,使其成为克服制药行业感染分析中分析瓶颈的有前途的解决方案,并且是学术研究中的常规方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/234b54f29585/ijms-25-08076-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/adc6cf2d4d21/ijms-25-08076-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/dbba3930dfdf/ijms-25-08076-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/772cef53249a/ijms-25-08076-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/171b2c09a691/ijms-25-08076-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/379f8cde9041/ijms-25-08076-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/7aa2aae0c9df/ijms-25-08076-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/234b54f29585/ijms-25-08076-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/adc6cf2d4d21/ijms-25-08076-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/dbba3930dfdf/ijms-25-08076-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/772cef53249a/ijms-25-08076-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/171b2c09a691/ijms-25-08076-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/379f8cde9041/ijms-25-08076-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/7aa2aae0c9df/ijms-25-08076-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c70/11311753/234b54f29585/ijms-25-08076-g007.jpg

相似文献

1
High-Throughput Determination of Infectious Virus Titers by Kinetic Measurement of Infection-Induced Changes in Cell Morphology.利用感染诱导的细胞形态变化的动力学测量进行高通量传染性病毒滴度的测定。
Int J Mol Sci. 2024 Jul 24;25(15):8076. doi: 10.3390/ijms25158076.
2
Automated, label-free TCID assay to determine the infectious titer of virus-based therapeutics.基于细胞的病毒感染性测定的自动化、无标记检测方法,用于测定病毒治疗药物的感染滴度。
J Virol Methods. 2022 Jan;299:114318. doi: 10.1016/j.jviromet.2021.114318. Epub 2021 Oct 6.
3
In vitro infectivity of oncolytic Newcastle Disease Virus: Correlation between plaque and fluorescent focus assays.溶瘤新城疫病毒的体外感染性:蚀斑试验与荧光灶试验之间的相关性
J Virol Methods. 2018 Jan;251:69-74. doi: 10.1016/j.jviromet.2017.09.029. Epub 2017 Oct 2.
4
Ionic Strength-Dependent, Reversible Pleomorphism of Recombinant Newcastle Disease Virus.离子强度依赖性重组新城疫病毒的可逆多形性。
J Virol. 2020 Oct 27;94(22). doi: 10.1128/JVI.01677-20.
5
Improvement of Precision in Recombinant Adeno-Associated Virus Infectious Titer Assay with Droplet Digital PCR as an Endpoint Measurement.采用微滴式数字 PCR 作为终点测量方法提高重组腺相关病毒感染滴度分析的精密度。
Hum Gene Ther. 2023 Aug;34(15-16):742-757. doi: 10.1089/hum.2023.014. Epub 2023 Jul 4.
6
Development of a high-throughput rubella virus infectivity assay based on viral activation of caspases.基于半胱天冬酶激活的高通量风疹病毒感染力测定法的建立。
J Virol Methods. 2010 Aug;167(2):199-204. doi: 10.1016/j.jviromet.2010.04.006. Epub 2010 Apr 22.
7
Development and application of a higher throughput RSV plaque assay by immunofluorescent imaging.通过免疫荧光成像技术开发和应用更高通量 RSV 噬斑检测法。
J Virol Methods. 2019 Jan;263:88-95. doi: 10.1016/j.jviromet.2018.10.022. Epub 2018 Oct 28.
8
Efficient fluorescence-based imaging methods for quantitating infectivity and oncolytic efficacy of Newcastle disease virus.基于荧光的高效成像方法,用于定量新城疫病毒的感染力和溶瘤效力。
J Virol Methods. 2010 Feb;163(2):390-7. doi: 10.1016/j.jviromet.2009.10.030. Epub 2009 Nov 13.
9
Evaluation of infectious titer in a candidate HSV type 2 vaccine by a quantitative molecular approach.采用定量分子方法评估候选 HSV-2 疫苗的感染滴度。
BMC Microbiol. 2013 Dec 6;13:284. doi: 10.1186/1471-2180-13-284.
10
A Comparative Analysis of Methods for Titering Reovirus.呼肠孤病毒滴度测定方法的比较分析
Pharm Nanotechnol. 2020;8(5):409-417. doi: 10.2174/2211738508666200826103322.

引用本文的文献

1
Navigating the Purification Process: Maintaining the Integrity of Replication-Competent Enveloped Viruses.探索纯化过程:维持有复制能力的包膜病毒的完整性
Vaccines (Basel). 2025 Apr 23;13(5):444. doi: 10.3390/vaccines13050444.
2
Navigating Uncertainties in RT-qPCR and Infectivity Assessment of Norovirus.应对诺如病毒实时定量聚合酶链反应及传染性评估中的不确定性
Food Environ Virol. 2025 Mar 8;17(1):22. doi: 10.1007/s12560-024-09632-0.

本文引用的文献

1
The Virus-Induced Cytopathic Effect.病毒诱导的细胞病变效应。
Subcell Biochem. 2023;106:197-210. doi: 10.1007/978-3-031-40086-5_7.
2
Functional design of experiment for potency assay optimization and in-silico simulation.效力测定优化的功能设计实验和计算机模拟。
J Pharm Biomed Anal. 2023 Sep 20;234:115584. doi: 10.1016/j.jpba.2023.115584. Epub 2023 Jul 16.
3
A rapid, high-throughput, viral infectivity assay using automated brightfield microscopy with machine learning.一种使用自动明场显微镜和机器学习的快速、高通量病毒感染性检测方法。
SLAS Technol. 2023 Oct;28(5):324-333. doi: 10.1016/j.slast.2023.07.003. Epub 2023 Jul 13.
4
Comparison among plaque assay, tissue culture infectious dose (TCID) and real-time RT-PCR for SARS-CoV-2 variants quantification.用于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株定量的蚀斑试验、组织培养感染剂量(TCID)和实时逆转录聚合酶链反应(RT-PCR)之间的比较。
Iran J Microbiol. 2022 Jun;14(3):291-299. doi: 10.18502/ijm.v14i3.9758.
5
Optimising cell-based bioassays via integrated design of experiments (ixDoE) - A practical guide.通过实验综合设计(ixDoE)优化基于细胞的生物测定——实用指南。
SLAS Discov. 2023 Jan;28(1):29-38. doi: 10.1016/j.slasd.2022.10.004. Epub 2022 Oct 28.
6
Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.单药或联合 ezabenlimab 治疗晚期和难治性实体瘤的 VSV-GP(BI 1831169)的 I 期研究。
Future Oncol. 2022 Aug;18(24):2627-2638. doi: 10.2217/fon-2022-0439. Epub 2022 Jun 14.
7
Viral vector-based gene therapies in the clinic.临床中基于病毒载体的基因疗法。
Bioeng Transl Med. 2021 Oct 20;7(1):e10258. doi: 10.1002/btm2.10258. eCollection 2022 Jan.
8
Automated, label-free TCID assay to determine the infectious titer of virus-based therapeutics.基于细胞的病毒感染性测定的自动化、无标记检测方法,用于测定病毒治疗药物的感染滴度。
J Virol Methods. 2022 Jan;299:114318. doi: 10.1016/j.jviromet.2021.114318. Epub 2021 Oct 6.
9
A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity.一种模块化的自佐剂癌症疫苗与溶瘤疫苗联合使用可诱导强烈的抗肿瘤免疫。
Nat Commun. 2021 Aug 31;12(1):5195. doi: 10.1038/s41467-021-25506-6.
10
Comparative growth kinetic study of Newcastle disease virus, infectious bursal disease virus and avian influenza virus in chicken embryo fibroblast and DF-1 cell lines.新城疫病毒、传染性法氏囊病病毒和禽流感病毒在鸡胚成纤维细胞和 DF-1 细胞系中的比较生长动力学研究。
Pol J Vet Sci. 2021 Jun;24(2):287-292. doi: 10.24425/pjvs.2021.137664.